Lactobacillus plantarum 299v (Lp299v) trials recruiting now
3 registrations that name lactobacillus plantarum 299v as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 3 registrations
Status
Phase
2US sites across 2 states
1
2 to 4
5 to 19
20 or more
All 3 registrations
RecruitingNCT07076849
Probiotic Supplementation in Optimizing Iron and Hematological Status Among Pregnant Females
Phase 2
University of Illinois at Chicago
About 250 people
Started Feb 1, 2026
In plain words A Phase 2 study of lactobacillus plantarum 299v in female participants 18 to 45, run by University of Illinois at Chicago. It plans to enroll about 250 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 to 45; healthy volunteers accepted. Conditions: Iron Deficiency (ID); Pregnancy.
singleton naturally conceived pregnancy;
at risk of IDA \[Hb 11.0 - 11.9 g/dL (first trimester) and Hb 10.5 - 11.5 g/dL (second trimester) based on new OB clinical complete blood count (CBC) results obtained from the EHR;
18 - 45 years old;
10-16 weeks GA;
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Lactiplantibacillus plantarum 299v; Placebo Capsule(s)
Registered summary
Maternal iron deficiency (ID) and iron deficiency anemia (IDA) is associated with maternal and infant mortality, spontaneous preterm birth, maternal postpartum hemorrhage, and neurocognitive defects in the neonate. Therefore, preventing maternal IDA in at-risk women is critical. The standard approach to improving iron status in pregnancy (i.e., oral iron supplements) is suboptimal and gastrointestinal discomforts associated with this approach (i.e., constipation) impairs adherence. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT07383701
Lactiplantibacillus Plantarum 299v Probiotic Supplementation in Patients With Diabetic Macular Edema
Phase 2
Massachusetts Eye and Ear Infirmary
About 36 people
Started Jun 23, 2026
In plain words A Phase 2 study of lactobacillus plantarum 299v in people 18 and older, run by Massachusetts Eye and Ear Infirmary. It plans to enroll about 36 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Diabetic Macular Edema.
Age of at least 18 years, presence of DME at the current clinical visit
The exclusion criteria are on the listing.
What it tests, as registered
Lactobacillus plantarum 299v
Registered summary
This pilot prospective, interventional, longitudinal study, aims to evaluate the potential benefits of the probiotic supplement Lactobacillus plantarum 299v in patients with diabetic macular edema (DME). The study seeks to address the following questions: 1. Does central macular thickness on optical coherence tomography decrease after 4 months of supplementation? 2. Is visual acuity improved at 1, 2, 3, and 4 months following initiation of supplementation? 3. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT06859437
Prevention of Clostridium Difficile Infections Using Lactobacillus Plantarum 299v Strain in Nephrology and Transplantation Department
No phase
Medical University of Silesia
About 300 people
Started Oct 1, 2024
In plain words A study of lactobacillus plantarum 299v in people 18 and older, run by Medical University of Silesia. It plans to enroll about 300 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Clostridioides Difficile Infection.
over 18 years old
organ transplantation or receiving immunosuppressive drugs for any other reasons
antibiotics therapy
The exclusion criteria are on the listing.
What it tests, as registered
Prevention of C. difficile infections using LP299v strain Placebo; Prevention of C. difficile infections using LP299v strain LP299v
Registered summary
The aim of this study was to analyze whether the use of the LP299v strain reduces the risk of Clostridium difficile infection (CDI) among patients receiving antibiotics and hospitalized in the nephrology and transplantation ward. Adutt patients from risk group (receiving immunosuppressive drugs and treated with antibiotics) were enrolled into study. Patients who meet the above criteria for inclusion in the study will be assigned to one of two groups. The full summary is on the listing.